초록접수 현황
| 16F-203 | 구연 발표 |
Prognostic Factors of Post-recurrence Survival in Patients with Completely Resected Stage III-N2 Non-small Cell Lung Cancer
Hyo Joon Jang, M.D.¹, Kyung Wook Shin, M.D.¹, Sukki Cho, M.D.¹,², Sung Won Yum¹, Kwhanmien Kim, M.D.¹,², Sanghoon Jheon, M.D.¹,²
¹Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea, ²Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea
Background : The aim of this study is to investigate the prognostic factors for PRS in patients with completely resected stage III-N2 NSCLC.
Methods : Two hundred forty-five patients were enrolled. A number of clinicopathological factors were evaluated to identify prognostic factors for recurrence by Cox proportional hazards models. The additional data including presence of recurrent symptom, recurrence patterns, treatment modality, use of targeted agents, and recurrence-free interval were evaluated to reveal the prognostic effects for PRS.
Results : One hundred twenty-four patients experienced recurrence during a median follow-up period of 36.3 months. Lymphatic invasion, tumor size, and number of positive LNs were worse prognostic factors for recurrence by multivariate analysis. Of 124 recurred patients, 21 patients (17%) were symptomatic at the time of initial recurrence. The mean recurrence-free interval was 14.0 months (≤ 12 months in 72, > 12 months in 52 patients). The patterns of recurrence were presented as loco-regional recurrence in 37 (30%), distant metastasis in 33 patients (27%), and both in 54 patients (43%). The types of initial treatment included surgery in 15 (12%), chemotherapy in 68 (55%), radiotherapy in 19 (15%), and chemo-radiation in 16 patients (13%). The median duration of PRS was 30.5 (1-109) months and the 2-year and 5-year of PRS were 54% and 23%, respectively. No symptom and a longer recurrence-free interval were independent prognostic factors for PRS.
Conclusion : No symptom at the time of recurrence and a longer recurrence-free interval were significant predictors of better PRS.
Methods : Two hundred forty-five patients were enrolled. A number of clinicopathological factors were evaluated to identify prognostic factors for recurrence by Cox proportional hazards models. The additional data including presence of recurrent symptom, recurrence patterns, treatment modality, use of targeted agents, and recurrence-free interval were evaluated to reveal the prognostic effects for PRS.
Results : One hundred twenty-four patients experienced recurrence during a median follow-up period of 36.3 months. Lymphatic invasion, tumor size, and number of positive LNs were worse prognostic factors for recurrence by multivariate analysis. Of 124 recurred patients, 21 patients (17%) were symptomatic at the time of initial recurrence. The mean recurrence-free interval was 14.0 months (≤ 12 months in 72, > 12 months in 52 patients). The patterns of recurrence were presented as loco-regional recurrence in 37 (30%), distant metastasis in 33 patients (27%), and both in 54 patients (43%). The types of initial treatment included surgery in 15 (12%), chemotherapy in 68 (55%), radiotherapy in 19 (15%), and chemo-radiation in 16 patients (13%). The median duration of PRS was 30.5 (1-109) months and the 2-year and 5-year of PRS were 54% and 23%, respectively. No symptom and a longer recurrence-free interval were independent prognostic factors for PRS.
Conclusion : No symptom at the time of recurrence and a longer recurrence-free interval were significant predictors of better PRS.
책임저자: Sukki Cho
Department of Thoracic and Cardiovascular Surgery, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Gyeonggi-do, Korea
발표자: Hyo Joon Jang, E-mail : 89422@snubh.org